
FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1
The FDA has accepted for review a New Drug Application (NDA) for doravirine/islatravir for adult patients with HIV-1 infection that is virologically suppressed on antiretroviral therapy, Merck announced in a release.1 The FDA set a Prescription Drug …